MX2021007835A - Polipeptidos utiles para edicion de genes y metodos de uso. - Google Patents

Polipeptidos utiles para edicion de genes y metodos de uso.

Info

Publication number
MX2021007835A
MX2021007835A MX2021007835A MX2021007835A MX2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A
Authority
MX
Mexico
Prior art keywords
interest
target sequence
binding
compositions
crispr
Prior art date
Application number
MX2021007835A
Other languages
English (en)
Spanish (es)
Inventor
Michael Lassner
Mark Moore
Tyson D Bowen
Tedd D Elich
Alexandra Briner Crawley
Rodolphe Barrangou
Original Assignee
Lifeedit Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifeedit Therapeutics Inc filed Critical Lifeedit Therapeutics Inc
Publication of MX2021007835A publication Critical patent/MX2021007835A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004Adenosine deaminase (3.5.4.4)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2021007835A 2018-12-27 2019-12-20 Polipeptidos utiles para edicion de genes y metodos de uso. MX2021007835A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862785391P 2018-12-27 2018-12-27
US201962790256P 2019-01-09 2019-01-09
US201962790261P 2019-01-09 2019-01-09
US201962790262P 2019-01-09 2019-01-09
US201962790258P 2019-01-09 2019-01-09
US201962790266P 2019-01-09 2019-01-09
US201962932169P 2019-11-07 2019-11-07
PCT/US2019/068079 WO2020139783A2 (en) 2018-12-27 2019-12-20 Polypeptides useful for gene editing and methods of use

Publications (1)

Publication Number Publication Date
MX2021007835A true MX2021007835A (es) 2021-08-11

Family

ID=69182752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007835A MX2021007835A (es) 2018-12-27 2019-12-20 Polipeptidos utiles para edicion de genes y metodos de uso.

Country Status (15)

Country Link
US (4) US20220145296A1 (enExample)
EP (2) EP3902911B1 (enExample)
JP (3) JP7572360B2 (enExample)
KR (1) KR20210149686A (enExample)
CN (1) CN113631704A (enExample)
AU (2) AU2019416108B2 (enExample)
BR (1) BR112021012665A2 (enExample)
ES (1) ES2970169T3 (enExample)
IL (2) IL312708A (enExample)
MX (1) MX2021007835A (enExample)
NZ (1) NZ778392A (enExample)
SG (1) SG11202106977PA (enExample)
TW (1) TW202039847A (enExample)
WO (1) WO2020139783A2 (enExample)
ZA (1) ZA202105281B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236566A1 (en) * 2018-06-05 2019-12-12 Lifeedit, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
TW202208626A (zh) * 2020-04-24 2022-03-01 美商生命編輯公司 Rna引導核酸酶及其活性片段與變體,以及使用方法
KR20230030618A (ko) 2020-07-01 2023-03-06 엘레바테바이오 테크놀로지스, 인코포레이티드 원형 rna를 사용하는 세포 리프로그래밍을 위한 조성물 및 방법
EP4182454A1 (en) * 2020-07-15 2023-05-24 Lifeedit Therapeutics, Inc. Uracil stabilizing proteins and active fragments and variants thereof and methods of use
AU2021339805A1 (en) 2020-09-11 2023-05-25 Life Edit Therapeutics, Inc. Dna modifying enzymes and active fragments and variants thereof and methods of use
AR125191A1 (es) 2021-03-22 2023-06-21 Lifeedit Therapeutics Inc Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso
WO2022241270A2 (en) * 2021-05-14 2022-11-17 Beam Therapeutics Inc. Compositions and methods for treating transthyretin amyloidosis
EP4101928A1 (en) * 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
BR112023023768A2 (pt) * 2021-06-11 2024-02-27 Bayer Ag Sistemas de endonucleases programáveis por rna tipo v
AU2022290278A1 (en) 2021-06-11 2024-01-04 LifeEDIT Therapeutics, Inc. Rna polymerase iii promoters and methods of use
JP2024534216A (ja) 2021-09-02 2024-09-18 サノフイ Rnaアフィニティー精製のための組成物および方法
CA3234107A1 (en) 2021-10-05 2023-04-13 Florent PERAL Methods for freezing and freeze-drying lipid nanoparticles (lnps) and lnps obtained with the same
EP4453191A1 (en) * 2021-12-23 2024-10-30 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
CA3248846A1 (en) 2022-01-17 2023-07-20 Sanofi Lipid Compounds and Their Uses
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023139557A1 (en) 2022-01-24 2023-07-27 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
EP4539858A1 (en) 2022-06-17 2025-04-23 Sanofi Pasteur Inc. Compositions and methods for circular rna affinity purification
CN120344660A (zh) 2022-07-18 2025-07-18 雷纳嘉德医疗管理公司 基因编辑组分、系统和使用方法
AU2023323547A1 (en) 2022-08-12 2025-03-20 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
CN120322549A (zh) 2022-08-25 2025-07-15 生命编辑治疗股份有限公司 利用锁核酸对向导rna化学修饰以用于rna引导的核酸酶介导的基因编辑
WO2024095245A2 (en) 2022-11-04 2024-05-10 LifeEDIT Therapeutics, Inc. Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
CA3277009A1 (en) 2022-12-16 2024-06-20 Life Edit Therapeutics, Inc. RNA GUIDELINES TARGETING THE TRAC GENE AND METHODS OF USE
EP4634383A1 (en) 2022-12-16 2025-10-22 Life Edit Therapeutics, Inc. Guide rnas that target foxp3 gene and methods of use
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
WO2024235991A1 (en) * 2023-05-15 2024-11-21 UCB Biopharma SRL Rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
WO2025003344A1 (en) * 2023-06-28 2025-01-02 Alia Therapeutics Srl Type ii cas proteins and applications thereof
WO2025022367A2 (en) 2023-07-27 2025-01-30 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025083619A1 (en) 2023-10-18 2025-04-24 Life Edit Therapeutics, Inc. Rna-guided nucleases and acive fragments and variants thereof and methods of use
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025174908A1 (en) 2024-02-12 2025-08-21 Life Edit Therapeutics, Inc. Novel rna-guided nucleases and proteins for polymerase editing
WO2025231360A1 (en) * 2024-05-03 2025-11-06 Modernatx, Inc. Novel cas nucleases and polynucleotides encoding the same

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5569597A (en) 1985-05-13 1996-10-29 Ciba Geigy Corp. Methods of inserting viral DNA into plant material
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4853331A (en) 1985-08-16 1989-08-01 Mycogen Corporation Cloning and expression of Bacillus thuringiensis toxin gene toxic to beetles of the order Coleoptera
US5268463A (en) 1986-11-11 1993-12-07 Jefferson Richard A Plant promoter α-glucuronidase gene construct
US5608142A (en) 1986-12-03 1997-03-04 Agracetus, Inc. Insecticidal cotton plants
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5039523A (en) 1988-10-27 1991-08-13 Mycogen Corporation Novel Bacillus thuringiensis isolate denoted B.t. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
WO1990011361A1 (en) 1989-03-17 1990-10-04 E.I. Du Pont De Nemours And Company External regulation of gene expression
DE69133128T2 (de) 1990-04-12 2003-06-18 Syngenta Participations Ag, Basel Gewebe-spezifische Promotoren
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5498830A (en) 1990-06-18 1996-03-12 Monsanto Company Decreased oil content in plant seeds
CA2051562C (en) 1990-10-12 2003-12-02 Jewel M. Payne Bacillus thuringiensis isolates active against dipteran pests
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5399680A (en) 1991-05-22 1995-03-21 The Salk Institute For Biological Studies Rice chitinase promoter
US5604121A (en) 1991-08-27 1997-02-18 Agricultural Genetics Company Limited Proteins with insecticidal properties against homopteran insects and their use in plant protection
TW261517B (enExample) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5608144A (en) 1994-08-12 1997-03-04 Dna Plant Technology Corp. Plant group 2 promoters and uses thereof
US5659026A (en) 1995-03-24 1997-08-19 Pioneer Hi-Bred International ALS3 promoter
US6072050A (en) 1996-06-11 2000-06-06 Pioneer Hi-Bred International, Inc. Synthetic promoters
WO1999043797A2 (en) 1998-02-26 1999-09-02 Pioneer Hi-Bred International, Inc. Constitutive maize promoters
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6555655B1 (en) 1999-05-04 2003-04-29 Monsanto Technology, Llc Coleopteran-toxic polypeptide compositions and insect-resistant transgenic plants
CN1390259A (zh) 1999-09-15 2003-01-08 孟山都技术有限公司 对鳞翅目昆虫有活性的苏云金芽孢杆菌δ内毒素组合物及其使用方法
JP4810062B2 (ja) 2001-12-17 2011-11-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス(aav)血清型8の配列
US20050183161A1 (en) 2003-10-14 2005-08-18 Athenix Corporation AXMI-010, a delta-endotoxin gene and methods for its use
WO2005066202A2 (en) 2003-12-22 2005-07-21 E.I. Du Pont De Nemours And Company Bacillus cry9 family members
AU2007260716B2 (en) 2006-06-14 2013-05-02 BASF Agricultural Solutions Seed US LLC Axmi-031, axmi-039, axmi-040 and axmi-049, a family of delta-endotoxin genes and methods for their use
EP3208339B1 (en) 2008-09-15 2019-05-01 The Children's Medical Center Corporation Modulation of bcl11a for treatment of hemoglobinopathies
WO2010132092A2 (en) 2009-05-12 2010-11-18 The Scripps Research Institute Cytidine deaminase fusions and related methods
EP2449109B1 (en) 2009-07-02 2016-09-28 Athenix Corporation Axmi-205 pesticidal gene and methods for its use
EP2513296A4 (en) * 2009-12-18 2013-05-22 Univ Leland Stanford Junior USE OF CYTIDINE DAMINASE ASSOCIATED ACTIVITIES TO PROMOTE DEMETHYLATION AND CELL REPROGRAMMEIRING
WO2011084324A2 (en) 2009-12-21 2011-07-14 Pioneer Hi-Bred International, Inc. Novel bacillus thuringiensis gene with lepidopteran activity
US8802934B2 (en) 2010-08-19 2014-08-12 Pioneer Hi Bred International Inc Bacillus thuringiensis gene with lepidopteran activity
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
US9121061B2 (en) * 2012-03-15 2015-09-01 New England Biolabs, Inc. Methods and compositions for discrimination between cytosine and modifications thereof and for methylome analysis
SI3401400T1 (sl) * 2012-05-25 2019-10-30 Univ California Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
CA2875618C (en) 2012-07-11 2021-04-27 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
CN113355357B (zh) * 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
EP3633032A3 (en) 2014-08-28 2020-07-29 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
AU2015101792A4 (en) * 2014-12-24 2016-01-28 Massachusetts Institute Of Technology Engineering of systems, methods and optimized enzyme and guide scaffolds for sequence manipulation
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA3000917A1 (en) * 2015-10-09 2017-04-13 Monsanto Technology Llc Rna-guided nucleases and uses thereof
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
EP3426778A1 (en) * 2016-03-11 2019-01-16 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
JP7588390B2 (ja) * 2016-10-14 2024-11-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのaav送達
EP3561059B1 (en) * 2016-12-23 2024-10-09 Institute for Basic Science Composition for base editing for animal embryo and base editing method
EP3572525A4 (en) * 2017-01-17 2020-09-30 Institute for Basic Science PROCEDURE FOR IDENTIFYING AN OFF-TARGET BASIC EDITING SITE BY BREAKING A SINGLE DNA STRAND
WO2018172556A1 (en) * 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
EP3625342B1 (en) * 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
CN109957569B (zh) * 2017-12-22 2022-10-25 苏州齐禾生科生物科技有限公司 基于cpf1蛋白的碱基编辑系统和方法
CN112961853B (zh) * 2018-11-02 2024-09-06 中国科学院动物研究所 基于C2c1核酸酶的基因组编辑系统和方法
AU2020329912A1 (en) * 2019-08-12 2022-03-24 Life Edit Therapeutics, Inc. RNA-guided nucleases and active fragments and variants thereof and methods of use

Also Published As

Publication number Publication date
US20250066783A1 (en) 2025-02-27
TW202039847A (zh) 2020-11-01
SG11202106977PA (en) 2021-07-29
US12188018B2 (en) 2025-01-07
AU2019416108A1 (en) 2021-08-12
NZ778392A (en) 2025-11-28
ES2970169T3 (es) 2024-05-27
US20220145296A1 (en) 2022-05-12
EP4339286A2 (en) 2024-03-20
JP2024137967A (ja) 2024-10-07
WO2020139783A3 (en) 2020-07-23
EP3902911B1 (en) 2023-12-13
JP2024050676A (ja) 2024-04-10
BR112021012665A2 (pt) 2021-11-03
KR20210149686A (ko) 2021-12-09
EP3902911A2 (en) 2021-11-03
US20250092398A1 (en) 2025-03-20
EP4339286A3 (en) 2024-08-28
EP3902911C0 (en) 2023-12-13
CN113631704A (zh) 2021-11-09
AU2025242270A1 (en) 2025-10-30
IL312708A (en) 2024-07-01
ZA202105281B (en) 2024-05-30
AU2019416108B2 (en) 2025-10-23
JP7572360B2 (ja) 2024-10-23
WO2020139783A2 (en) 2020-07-02
US20230272398A1 (en) 2023-08-31
JP2022516130A (ja) 2022-02-24
IL284400A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
ZA202105281B (en) Polypeptides useful for gene editing and methods of use
EP4512900A3 (en) Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2022056254A3 (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
MX2022013187A (es) Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.
BR112022002695A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
ZA202103277B (en) Programmable dna base editing by nme2cas9-deaminase fusion proteins
PH12021551114A1 (en) Crispr-cas12j enzyme and system
EP4269577A3 (en) Nucleobase editors and uses thereof
PH12019501335A1 (en) Thermostable cas9 nucleases
WO2019139645A3 (en) High efficiency base editors comprising gam
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
MX2019004499A (es) Sistemas de replicón de virus recombinante y usos de estos.
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
MX2023010640A (es) Péptidos neoantigénicos transmembranales.
BR112021007503A2 (pt) Proteína de fusão, molécula de ácido nucleico, método para edição de material genético, e, sistemas para edição de material genético e para distribuição de componentes de edição de genoma
WO2020006131A3 (en) Nucleases for genome editing
WO2019084362A3 (en) Fusion protein and nucleic acid molecule for exogenous stimulant-dependent stress granule assembly
ATE518881T1 (de) Grampositive bakterienzellen enthaltend ein unterbrochenes flagellingen, fusionsproteine auf flagellinbasis und deren verwendung zum entfernen von metallionen aus einer flüssigkeit
MX2025001766A (es) Nucleasas guiadas por acido ribonucleico (arn) y fragmentos activos y variantes de las mismas y metodos de uso
EA202191788A1 (ru) Полипептиды, применимые для редактирования генов, и способы их применения
AR117535A1 (es) Polipéptidos útiles para edición de genes y métodos de uso
EA202092929A1 (ru) Рнк-управляемые нуклеазы и активные фрагменты и их варианты и способы применения
WO2000031133A3 (en) Potassium channel interactors and uses therefor
WO2025022367A3 (en) Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2024007010A3 (en) Gene editing compositions and methods of use thereof